Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New microchip tracks antibody-virus interactions from a single drop of blood

A new microchip invented by Scripps Research scientists can reveal how a person's antibodies interact with viruses-using just a drop of blood.

12 Jul 2025

WHO, ITU, WIPO release a new technical brief on using AI in traditional medicine

Artificial intelligence (AI) is ushering in a transformative era for traditional medicine, one where centuries-old healing systems are enhanced by cutting-edge technologies to deliver more safe, personalized, effective, and accessible care.

11 Jul 2025

Innovative approach for the development of next-generation cancer therapies targeting FGFR2/3

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers.

4 Jul 2025

Shaping the future of lab automation through AI and robotics

Discover how Chemspeed is revolutionizing lab automation with AI-driven workflows, modular robotics, and more

From Bruker BioSpin Division 3 Jul 2025

Measuring tumor force offers new clues for brain cancer treatment

As brain tumors grow, they must do one of two things: push against the brain or use finger-like extensions to invade and destroy surrounding tissue.

3 Jul 2025

Breakthrough AI uncovers promising Rett syndrome treatment

Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it and much fewer boys.

2 Jul 2025

Aromatic benzaldehyde inhibits growth of therapy-resistant pancreatic cancer

During therapy, some cancer cells evolve to escape elimination. Newer anticancer drugs that can overcome this resistance are necessary.

2 Jul 2025

Optibrium partners with TalTech on EU-funded PhD program to advance sustainable drug discovery

Optibrium, a leading developer of software and AI solutions for molecular design, today announced its partnership with TalTech (Tallinn University of Technology) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme.

2 Jul 2025

New tool reveals hidden water patterns in protein structures

Every protein in the body is encased in a water shell that directs protein structure, provides vital stability and steers function.

30 Jun 2025

Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical trial (NCT06414460) to evaluate ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumors.

27 Jun 2025

Enhanced Genomics and The ALBORADA Drug Discovery Institute partner to accelerate Alzheimer's drug discovery

Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.

25 Jun 2025

Diabetes drug semaglutide shows promise in reducing dementia risk

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D).

24 Jun 2025

Driving breakthroughs for the NF community at the 2025 NF Conference

A new era is unfolding for the NF community. With two FDA-approved treatments now on the market - including the first-ever therapy for adults with NF1 - and cutting-edge advances in AI, drug repositioning, and precision medicine, momentum is building like never before.

20 Jun 2025

Scientists develop tool to predict bowel cancer drug resistance

Scientists have developed a tool that can predict how bowel cancer adapts to treatment – helping researchers to design new personalized drugs that will keep patients living well for longer.

20 Jun 2025

New 3D immunohistochemistry method enhances deep tissue imaging

Three dimensional immunohistochemistry (3D-IHC) has transformed our ability to visualize the spatial arrangement of cells and molecules in intact tissues.

19 Jun 2025

C-Path’s TRxA awards $250,000 grant to develop novel treatment for type 1 diabetes

Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D).

19 Jun 2025

New dual-adjuvant vaccine strategy offers hope in the fight against HIV

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They found that a two-part delivery strategy can train the immune system to produce a stronger response to HIV, offering new hope in the fight against one of the world's most elusive viruses.

19 Jun 2025

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

PDE3 inhibitors show promise in promoting bone growth

Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either end of a bone.

17 Jun 2025

Indiana University researcher helps develop FDA-approved Alzheimer’s test

A first-of-its-kind blood test to detect amyloid plaques in the brain associated with Alzheimer's disease recently received clearance from the U.S. Food and Drug Administration. An Indiana University School of Medicine researcher who helped lead the discovery and development of one of the biomarkers the test identifies hopes it will provide greater access and a more accurate diagnosis for patients.

16 Jun 2025